Review of randomized clinical trials of donor management and organ preservation in deceased donors: Opportunities and issues

Transplantation

Volumn 94, Issue 5, 2012, Pages 425-441

  Dikdan, George S ^a   Mora Esteves, Cesar ^a   Koneru, Baburao ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

Clinical trials; Deceased donors; Donor management; Preconditioning.; Preservation solutions; Pulsatile perfusion; Randomized trials

Indexed keywords

ADRENALIN; ARGIPRESSIN; CASPASE INHIBITOR; CELSIOR; CYCLOPHOSPHAMIDE; DESMOPRESSIN; DILTIAZEM; DOPAMINE; GELATIN; HETASTARCH; HYDRAZINE DERIVATIVE; HYDROCORTISONE; ILOPROST; INSULIN; LIOTHYRONINE; MANNITOL; METHYLPREDNISOLONE; OPIATE; PANCASPASE INHIBITOR; PAPAVERINE; PHENOXYBENZAMINE; PHENTOLAMINE; PHENTOLAMINE MESYLATE; PLACEBO; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN E1; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

ANATOMICAL VARIATION; BRAIN DEATH; CADAVER DONOR; CRYOPRECIPITATE; CRYOPRESERVATION; CRYSTALLOID; FLUID RESUSCITATION; FUNDING; HEART DEATH; HEART TRANSPLANTATION; HEMODYNAMICS; HORMONAL THERAPY; HUMAN; ISCHEMIA; ISCHEMIC PRECONDITIONING; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; NONHUMAN; ORGAN DONOR; ORGAN PRESERVATION; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW;

CYTOPROTECTION; DONOR SELECTION; HUMANS; ORGAN PRESERVATION; ORGAN PRESERVATION SOLUTIONS; ORGAN TRANSPLANTATION; PERFUSION; PROTECTIVE AGENTS; PULSATILE FLOW; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS;

EID: 84866326257     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182547537     Document Type: Review

References (151)

1. Pérez-Blanco A, Caturla-Such J, Canovas-Robles J, et al. Efficiency of triiodothyronine treatment on organ donor hemodynamic management and adenine nucleotide concentration. Intensive Care Med 2005; 31: 943.
2. Powner DJ, Hendrich A, Lagler RG, et al. Hormonal changes in brain dead patients. Crit Care Med 1990; 18: 702.
3. Gramm HJ, Meinhold H, Bickel U, et al. Acute endocrine failure after brain death? Transplantation 1992; 54: 851.
4. Novitzky D, Cooper DK, Rosendale JD, et al. Hormonal therapy of the brain-dead organ donor: experimental and clinical studies. Transplantation 2006; 82: 1396.
5. Venkateswaran RV, Steeds RP, Quinn DW, et al. The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. Eur Heart J 2009; 30: 1771.
6. Chen EP, Bittner HB, Kendall SW, et al. Hormonal and hemody-namic changes in a validated animal model of brain death. Crit Care Med 1996; 24: 1352.
7. Novitzky D, Cooper DK, Morrell D, et al. Change from aerobic to anaerobic metabolism after brain death, and reversal following tri-iodothyronine therapy. Transplantation 1988; 45: 32.
8. Blaine EM, Tallman RD Jr, Frolicher D, et al. Vasopressin supplementation in a porcine model of brain-dead potential organ donors. Transplantation 1984; 38: 459.
9. Lyons JM, Pearl JM, McLean KM, et al. Glucocorticoid administration reduces cardiac dysfunction after brain death in pigs. J Heart Lung Transplant 2005; 24: 2249.
10. Guesde R, Barrou B, Leblanc I, et al. Administration of desmopres-sin in brain-dead donors and renal function in kidney recipients. Lancet 1998; 352: 1178.
11. Schneider A, Toledo-Pereyra LH, Zeichner WD, et al. Effect of do-pamine and pitressin on kidneys procured and harvested for transplantation. Transplantation 1983; 36: 110.
12. Goldsmith SR. Vasopressin as vasopressor. Am J Med 1987; 82: 1213.
13. Pennefather SH, Bullock RE, Mantle D, et al. Use of low dose argi-nine vasopressin to support brain-dead organ donors. Transplantation 1995; 59: 58.
14. Kinoshita Y, Yahata K, Yoshioka T, et al. Long-term renal preservation after brain death maintained with vasopressin and epineph-rine. Transpl Int 1990; 3: 15.
15. Rosendale JD, Kauffman HM, McBride MA, et al. Aggressive phar-macologic donor management results in more transplanted organs. Transplantation 2003; 75: 482.
16. Orlowski JP, Spees EK. Improved cardiac transplant survival with thyroxine treatment of hemodynamically unstable donors: 95.2% graft survival at 6 and 30 months. Transplant Proc 1993; 25: 1535. (Pubitemid 23079090)
17. Jeevanandam V. Triiodothyronine: spectrum of use in heart transplantation. Thyroid 1997; 7: 139.
18. Zuppa AF, Nadkarni V, Davis L, et al. The effect of a thyroid hormone infusion on vasopressor support in critically ill children with cessation of neurologic function. Crit Care Med 2004; 32: 2318.
19. Nath DS, Ilias Basha H, Liu MH, et al. Increased recovery of thoracic organs after hormonal resuscitation therapy. J Heart Lung Transplant 2010; 29: 594.
20. Mariot J, Jacob F, Voltz C, et al. Value of hormonal treatment with triiodothyronine and cortisone in brain dead patients [in French]. Ann Franc Anesth Reanim 1991; 10: 321.
21. Garcia-Fages LC, Antolin M, Cabrer C, et al. Effects of substitu-tive triiodothyronine therapy on intracellular nucleotide levels in donor organs. Transplant Proc 1991; 23: 2495.
22. Randell TT, Hockerstedt KA. Triiodothyronine treatment in brain-dead multiorgan donorsVa controlled study. Transplantation 1992; 54: 736.
23. Goarin JP, Cohen S, Riou B, et al. The effects of triiodothyronine on hemodynamic status and cardiac function in potential heart donors. Anesth Analg 1996; 83: 41.
24. Venkateswaran RV, Patchell VB, Wilson IC, et al. Early donor management increases the retrieval rate of lungs for transplantation. Ann Thorac Surg 2008; 85: 278.
25. Randell T, Orko R, Hockerstedt K. Peroperative fluid management of the brain-dead multiorgan donor. Acta Anaesthesiol Scand 1990; 34: 592.
26. Cittanova ML, Leblanc I, Legendre C, et al. Effect of hydro-xyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620.
27. Dienst SG, MacDonald R, Toledo-Pereyra LH, et al. Modification of donor pretreatment prolongs canine renal allograft survival. Transplant Proc 1979; 11: 1465.
28. Zincke H, Woods JE. Donor pretreatment in cadaver renal transplantation. Surg Gynecol Obstet 1977; 145: 183.
29. Zincke H, Woods JE, Holley KE. Effect of high doses of intravenous methylprednisolone and cyclophosphamide on renal homo-grafts. Urology 1977; 10: 301.
30. Guttmann RD, Morehouse DD, Meakins JL, et al. Donor pretreat-ment in an unselected series of cadaver renal allografts. Kidney Int Suppl 1978; (8): S99.
31. Dienst SG. Statewide donor pretreatment study. Transplant Proc 1977; 9: 1597.
32. Chatterjee SN, Terasaki PI, Fine S, et al. Pretreatment of cadaver donors with methylprednisolone in human renal allografts. Surg Gynecol Obstet 1977; 145: 729.
33. Chatterjee SN, Smith R, Fine S, et al. A prospective randomized double-blind controlled study of cadaver donor pretreatment with cyclophosphamide in human renal transplantation. Transplant Proc 1981; 13: 709.
34. Soulillou JP, Baron D, Rouxel A, et al. Steroid-cyclophosphamide pretreatment of kidney allograft donors. A control study. Nephron 1979; 24: 193.
35. Pratschke J, Kofla G, Wilhelm MJ, et al. Improvements in early behavior of rat kidney allografts after treatment of the brain-dead donor. Ann Surg 2001; 234: 732.
36. Follette DM, Rudich SM, Babcock WD. Improved oxygenation and increased lung donor recovery with high-dose steroid administration after brain death. J Heart Lung Transplant 1998; 17: 423.
37. Rosendale JD, Kauffman HM, McBride MA, et al. Hormonal resuscitation yields more transplanted hearts, with improved early function. Transplantation 2003; 75: 1336.
38. Kainz A, Wilflingseder J, Mitterbauer C, et al. Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: a randomized, controlled trial. Ann Intern Med 2010; 153: 222.
39. Kotsch K, Ulrich F, Reutzel-Selke A, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg 2008; 248: 1042.
40. Rosendale JD, Chabalewski FL, McBride MA, et al. Increased transplanted organs from the use of a standardized donor management protocol. Am J Transplant 2002; 2: 761.
41. Selck FW, Deb P, Grossman EB. Deceased organ donor characteristics and clinical interventions associated with organ yield. Am J Transplant 2008; 8: 965.
42. Duggan KA, Macdonald GJ, Charlesworth JA, et al. Verapamil prevents post-transplant oliguric renal failure. Clin Nephrol 1985; 24: 289.
43. Koller J, Wieser C, Kornberger R, et al. Does systemic pretreat-ment with verapamil prevent acute tubular necrosis after renal transplantation? Transplant Proc 1988; 20: 905.
44. Neumayer HH, Schreiber M, Wagner K. Prevention of delayed graft function by diltiazem and iloprost. Transplant Proc 1989; 21: 1221.
45. Schnuelle P, Gottmann U, Hoeger S, et al. Effects of donor pre-treatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009; 302: 1067.
46. 2 before retrieval decreases hepa-tocellular ischemia-reperfusion injury. Transplantation 1999; 67: 1128.
47. Pontin AR, Ovnat A, Jacobson JE, et al. Protective effect of vasodilators in donors requiring pressor support. Transpl Int 1992; 5: S110.
48. Desai KK, Dikdan GS, Shareef A, et al. Ischemic preconditioning of the liver: a few perspectives from the bench to bedside translation. Liver Transpl 2008; 14: 1569.
49. Azoulay D, Del Gaudio M, Andreani P, et al. Effects of 10 minutes of ischemic preconditioning of the cadaveric liver on the graft's preservation and function: the ying and the yang. Ann Surg 2005; 242: 133.
50. Koneru B, Fisher A, He Y, et al. Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy. Liver Transpl 2005; 11: 196.
51. Cescon M, Grazi GL, Grassi A, et al. Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study. Liver Transpl 2006; 12: 628.
52. Amador A, Grande L, Marti J, et al. Ischemic pre-conditioning in deceased donor liver transplantation: a prospective randomized clinical trial. Am J Transplant 2007; 7: 2180.
53. Koneru B, Shareef A, Dikdan G, et al. The ischemic preconditioning paradox in deceased donor liver transplantationVevidence from a prospective randomized single blind clinical trial. Am J Transplant 2007; 7: 2788.
54. Franchello A, Gilbo N, David E, et al. Ischemic preconditioning (IP) of the liver as a safe and protective technique against ischemia/re-perfusion injury (IRI). Am J Transplant 2009; 9: 1629.
55. Gurusamy KS, Kumar Y, Sharma D, Davidson BR. Ischaemic preconditioning for liver transplantation. Cochrane Database Syst Rev 2008; (1): CD006315.
56. Beck-Schimmer B, Breitenstein S, Urech S, et al. A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg 2008; 248: 909.
57. Guarracino F, Landoni G, Tritapepe L, et al. Myocardial damage prevented by volatile anesthetics: a multicenter randomized controlled study. J Cardiothorac Vasc Anesth 2006; 20: 477.
58. Lucchinetti E, Wacker J, Maurer C, et al. Helium breathing provides modest antiinflammatory, but no endothelial protection against ische-mia-reperfusion injury in humans in vivo. Anesth Analg 2009; 109: 101.
59. Hanto DW, Maki T, Yoon MH, et al. Intraoperative administration of inhaled carbon monoxide reduces delayed graft function in kidney allografts in swine. Am J Transplant 2010; 10: 2421.
60. Ikeda A, Ueki S, Nakao A, et al. Liver graft exposure to carbon monoxide during cold storage protects sinusoidal endothelial cells and ameliorates reperfusion injury in rats. Liver Transpl 2009; 15: 1458.
61. Oeltgen PR, Horton ND, Bolling SF, et al. Extended lung preservation with the use ofhibernation trigger factors. Ann Thorac Surg 1996; 61: 1488.
62. Sigg DC, Coles JA Jr, Gallagher WJ, et al. Opioid preconditioning: myocardial function and energy metabolism. Ann Thorac Surg 2001; 72: 1576.
63. Donckier V, Loi P, Closset J, et al. Preconditioning of donors with interleukin-10 reduces hepatic ischemia-reperfusion injury after liver transplantation in pigs. Transplantation 2003; 75: 902.
64. Gohrbandt B, Fischer S, Warnecke G, et al. Glycine intravenous donor preconditioning is superior to glycine supplementation to low-potassium dextran flush preservation and improves graft function in a large animal lung transplantation model after 24 hours of cold ischemia. J Thorac Cardiovasc Surg 2006; 131: 724.
65. Nowak K, Hanusch C, Nicksch K, et al. Pre-ischaemic conditioning of the pulmonary endothelium by immunotargeting of catalase via angiotensin-converting- enzyme antibodies. Eur J Cardiothorac Surg 2010; 37: 859.
66. Rey MM, Ware LB, Matthay MA, et al. Informed consent in research to improve the number and quality of deceased donor organs. Crit Care Med 2011; 39: 280.
67. Feng S. Donor intervention and organ preservation: where is the science and what are the obstacles? Am J Transplant 2010; 10: 1155.
68. Mora-Esteves C, Koneru B. Resolving issues of consent and oversight: one step closer to terra firma in deceased organ donor research. Crit Care Med 2011; 39: 400.
69. Murugan R, Venkataraman R, Wahed AS, et al. Increased plasma interleukin-6 in donors is associated with lower recipient hospital-free survival after cadaveric organ transplantation. Crit Care Med 2008; 36: 1810.
70. Hollmen ME, Kyllonen LE, Inkinen KA, et al. Urine neutrophil gela-tinase-associated lipocalin is a marker of graft recovery after kidney transplantation. Kidney Int 2011; 79: 89.
71. Kalayoglu M, Sollinger HW, Stratta RJ, et al. Extended preservation of the liver for clinical transplantation. Lancet 1988; 1: 617.
72. Nardo B, Bertelli R, Montalti R, et al. Preliminary results of a clinical randomized study comparing Celsior and HTK solutions in liver preservation for transplantation. Transplant Proc 2005; 37: 320.
73. Meine MH, Zanotelli ML, Neumann J, et al. Randomized clinical assay for hepatic grafts preservation with University of Wisconsin or histidine- tryptophan-ketoglutarate solutions in liver transplantation. Transplant Proc 2006; 38: 1872.
74. Pedotti P, Cardillo M, Rigotti P, et al. A comparative prospective study of two available solutions for kidney and liver preservation. Transplantation 2004; 77: 1540.
75. Ploeg RJ, van Bockel JH, Langendijk PT, et al. Effect of preservation solutionon resultsof cadaveric kidney transplantation. The European Multicentre Study Group. Lancet 1992; 340: 129.
76. de Boer J, De Meester J, Smits JM, et al. Eurotransplant randomized multicenter kidney graft preservation study comparing HTK with UW and Euro-Collins. Transpl Int 1999; 12: 447.
77. Montalti R, Nardo B, Capocasale E, et al. Kidney transplantation from elderly donors: a prospective randomized study comparing celsior and UW solutions. Transplant Proc 2005; 37: 2454.
78. Faenza A, Catena F, Nardo B, et al. Kidney preservation with university of Wisconsin and Celsior solution: a prospective multicen-ter randomized study. Transplantation 2001; 72: 1274.
79. Nicoluzzi J, Macri M, Fukushima J, et al. Celsior versus Wisconsin solution in pancreas transplantation. Transplant Proc 2008; 40: 3305.
80. Klaus F, Castro DB, Bittar CM, et al. Kidney transplantation with Belzer or Custodiol solution: a randomized prospective study. Transplant Proc 2007; 39: 353.
81. Ishibashi M, Kokado Y, Takahara S, et al. Randomized multicenter study for comparison of University of Wisconsin solution vs Euro-Collins solution on early renal allograft function in the nonYheart-beating cadaver donor. Transplant Proc 1994; 26: 2405.
82. Moisiuk Y, Tarabarko N, Vitjazev G, et al. Histidine-tryptophan- ketoglutarate versus Euro-Collins for preservation of kidneys from nonYheart-beating donors. Transplant Proc 1996; 28: 202. (Pubitemid 26073701)
83. Gok MA, Shenton BK, Buckley PE, et al. How to improve the quality of kidneys from nonYheart-beating donors: a randomised controlled trial of thrombolysis in nonYheart-beating donors. Transplantation 2003; 76: 1714.
84. Boggi U, Vistoli F, Del Chiaro M, et al. Pancreas preservation with University of Wisconsin and Celsior solutions: a single-center, prospective, randomized pilot study. Transplantation 2004; 77: 1186.
85. Schneeberger S, Biebl M, Steurer W, et al. A prospective randomized multicenter trial comparing histidine-tryptophane-ketoglutarate versus University of Wisconsin perfusion solution in clinical pancreas transplantation. Transpl Int 2009; 22: 217.
86. Wildhirt SM, Weis M, Schulze C, et al. Effects of Celsior and University of Wisconsin preservation solutions on hemodynamics and endothelial function after cardiac transplantation in humans: a single-center, prospective, randomized trial. Transpl Int 2000; 13 Suppl 1: S203.
87. Jeevanandam V, Barr ML, Auteri JS, et al. University of Wisconsin solution versus crystalloid cardioplegia for human donor heart preservation. A randomized blinded prospective clinical trial. J Thorac Cardiovasc Surg 1992; 103: 194.
88. Stein DG, Drinkwater DC Jr, Laks H, et al. Cardiac preservation in patients undergoing transplantation. A clinical trial comparing University of Wisconsin solution and Stanford solution. J Thorac Car-diovasc Surg 1991; 102: 657.
89. Demertzis S, Wippermann J, Schaper J, et al. University of Wisconsin versus St. Thomas' Hospital solution for human donor heart preservation. Ann Thorac Surg 1993; 55: 1131.
90. Luciani GB, Faggian G, Montalbano G, et al. Blood versus crystalloid cardioplegia for myocardial protection of donor hearts during transplantation: a prospective, randomized clinical trial. J Thorac Cardiovasc Surg 1999; 118: 787.
91. Wieselthaler GM, Chevtchik O, Konetschny R, et al. Improved graft function using a new myocardial preservation solution: Celsior. Preliminary data from a randomized prospective study. Transplant Proc 1999; 31: 2067.
92. Vega JD, Ochsner JL, Jeevanandam V, et al. A multicenter, randomized, controlled trial of Celsior for flush and hypothermic storage of cardiac allografts. Ann Thorac Surg 2001; 71: 1442.
93. Okada Y, Kondo T. Preservation solution for lung transplantation. Gen Thorac Cardiovasc Surg 2009; 57: 635.
94. D'Armini AM, Grande AM, Rinaldi M, et al. Prospective randomized clinical study of Celsior vs University of Wisconsin in double lung transplant. J Heart Lung Transplant 2001; 20: 183.
95. Arnaoutakis GJ, Allen JG, Merlo CA, et al. Low potassium dextran is superior to University of Wisconsin solution in high-risk lung transplant recipients. J Heart Lung Transplant 2010; 29: 1380.
96. Stewart ZA, Cameron AM, Singer AL, et al. Histidine-tryptophan- ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. Am J Transplant 2009; 9: 286.
97. Stewart ZA, Lonze BE, Warren DS, et al. Histidine-tryptophan- ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants. Am J Transplant 2009; 9: 1048.
98. Stewart ZA, Cameron AM, Singer AL, et al. Histidine-tryptophan- ketoglutarate (HTK) is associated with reduced graft survival in pancreas transplantation. Am J Transplant 2009; 9: 217.
99. George TJ, Arnaoutakis GJ, Baumgartner WA, et al. Organ storage with University of Wisconsin solution is associated with improved outcomes after orthotopic heart transplantation. J Heart Lung Transplant 2011; 30: 1033.
100. Thuillier R, Dutheil D, Trieu MT, et al. Supplementation with a new therapeutic oxygen carrier reduces chronic fibrosis and organ dysfunction in kidney static preservation. Am J Transplant 2011; 11: 1845.
101. Bezinover D, Ramamoorthy S, Uemura T, et al. Use of a third-generation perfluorocarbon for preservation of rat DCD liver grafts. J Surg Res 2012; 175: 131.
102. Thuillier R, Renard C, Rogel-Gaillard C, et al. Effect of polyethylene glycolYbased preservation solutions on graft injury in experimental kidney transplantation. Br J Surg 2011; 98: 368.
103. Stowe DF, Camara AK, Heisner JS, et al. Ten-hour preservation of guinea pig isolated hearts perfused at low flow with air-saturated Lifor solution at 26{degrees}C: comparison to ViaSpan solution. Am J Physiol Heart Circ Physiol 2007; 293: H895.
104. Ahmad N, Pratt JR, Potts DJ, et al. Comparative efficacy of renal preservation solutions to limit functional impairment after warm is-chemic injury. Kidney Int 2006; 69: 884.
105. Hing AJ, Watson A, Hicks M, et al. Combining cariporide with glyceryl trinitrate optimizes cardiac preservation during porcine heart transplantation. Am J Transplant 2009; 9: 2048.
106. Jabbour A, Gao L, Kwan J, et al. A recombinant human neuregulin-1 peptide improves preservation of the rodent heart after prolonged hypothermic storage. Transplantation 2011; 91: 961.
107. Sterling WA, Pierce JC, Hutcher NE, et al. A comparison of hypo-thermic preservation with hypothermic pulsatile perfusion in paired human kidneys. Surgical forum 1971; 22: 229.
108. Alijani MR, Cutler JA, DelValle CJ, et al. Single-donor cold storage versus machine perfusion in cadaver kidney preservation. Transplantation 1985; 40: 659.
109. Heil JE, Canafax DM, Sutherland DE, et al. A controlled comparison of kidney preservation by two methods: machine perfusion and cold storage. Transplant Proc 1987; 19: 2046.
110. Mendez R, Mendez RG, Koussa N, et al. Preservation effect on oligo-anuria in the cyclosporine era: a prospective trial with 26 paired cadaveric renal allografts. Transplant Proc 1987; 19: 2047.
111. Matsuno N, Sakurai E, Tamaki I, et al. The effect of machine per-fusion preservation versus cold storage on the function of kidneys from nonYheart-beating donors. Transplantation 1994; 57: 293.
112. Marshall VC, Ross H, Scott DF, et al. Preservation of cadaver of renal allografts: comparison of ice storage and machine perfusion. Med J Aust 1977; 2: 353.
113. Feduska NJ, Collins GM, Amend WJ, et al. Comparative study of albumin solution and cryoprecipitated plasma for renal preservation: a preliminary report. Transplant Proc 1979; 11: 472.
114. Halloran P, Aprile M. A randomized prospective trial of cold storage versus pulsatile perfusion for cadaver kidney preservation. Transplantation 1987; 43: 827.
115. Merion RM, Oh HK, Port FK, et al. A prospective controlled trial of cold-storage versus machine-perfusion preservation in cadaveric renal transplantation. Transplantation 1990; 50: 230.
116. Veller MG, Botha JR, Britz RS, et al. Renal allograft preservation: a comparison of University of Wisconsin solution and of hypo-thermic continuous pulsatile perfusion. Clin Transplant 1994; 8: 97.
117. Mozes MF, Finch WT, Reckard CR, et al. Comparison of cold storage and machine perfusion in the preservation of cadaver kidneys: a prospective, randomized study. Transplant Proc 1985; 17: 1474.
118. Wight JP, Chilcott JB, Holmes MW, et al. Pulsatile machine perfu-sion vs. cold storage of kidneys for transplantation: a rapid and systematic review. Clin Transplant 2003; 17: 293.
119. Schold JD, Kaplan B, Howard RJ, et al. Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation. Am J Transplant 2005; 5: 1681.
120. Moers C, Smits JM, Maathuis MH, et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009; 360: 7.
121. Jochmans I, Moers C, Smits JM, et al. Machine perfusion versus cold storage for the preservation of kidneys donated after cardiac death: a multicenter, randomized, controlled trial. Ann Surg 2010; 252: 756.
122. Watson CJ, Wells AC, Roberts RJ, et al. Cold machine perfusion versus static cold storage of kidneys donated after cardiac death: a UK multicen-ter randomized controlled trial. Am J Transplant 2010; 10: 1991.
123. Taylor MJ, Baicu SC. Current state of hypothermic machine perfu-sion preservation of organs: the clinical perspective. Cryobiology 2010; 60(3 Suppl): S20.
124. 1 influences pulsatile preservation characteristics and early graft function in expanded criteria donor kidneys. J Surg Res 1999; 85: 17.
125. Polyak MM, Arrington BO, Kapur S, et al. Donor treatment with phentolamine mesylate improves machine preservation dynamics and early renal allograft function. Transplantation 2000; 69: 184.
126. Matsuno N, Kozaki K, Degawa H, et al. A useful predictor in machine perfusion preservation for kidney transplantation from nonYheart-beating donors. Transplant Proc 2000; 32: 173.
127. Kievit JK, Nederstigt AP, Oomen AP, et al. Release of alpha-glutathione S-transferase (alpha GST) and pi-glutathione S-transferase (pi GST) from ischemic damaged kidneys into the machine perfusateV relevance to viability assessment. Transplant Proc 1997; 29: 3591.
128. de Vries B, Snoeijs MG, von Bonsdorff L, et al. Redox-active iron released during machine perfusion predicts viability of ischemically injured deceased donor kidneys. Am J Transplant 2006; 6: 2686.
129. Moers C, Varnav OC, van Heurn E, et al. The value of machine perfusion perfusate biomarkers for predicting kidney transplant outcome. Transplantation 2010; 90: 966.
130. Dutkowski P, de Rougemont O, Clavien PA. Machine perfusion for 'marginal' liver grafts. Am J Transplant 2008; 8: 917.
131. Guarrera JV, Henry SD, Samstein B, et al. Hypothermic machine preservation in human liver transplantation: the first clinical series. Am J Transplant 2010; 10: 372.
132. Cobert ML, West LM, Jessen ME. Machine perfusion for cardiac allograft preservation. Curr Opin Organ Transplant 2008; 13: 526.
133. Schnitzler MA, Lentine KL, Axelrod D, et al. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials. Transplantation 2012; 93: 172.
134. Jeffery JR, Downs A, Grahame JW, et al. A randomized prospective study of cadaver donor pretreatment in renal transplantation. Transplantation 1978; 25: 287.
135. Schwartz ME, Nishizaki T, Thung SN, et al. Initial flush solution for donor liver procurement: lactated Ringers' or UW solution? A randomized, prospective trial. Transplant Proc 1991; 23: 1554.
136. Cofer JB, Klintmalm GB, Morris CV, et al. A prospective randomized trial between Euro-Collins and University of Wisconsin solutions as the initial flush in hepatic allograft procurement. Transplantation 1992; 53: 995.
137. Kurzawinski TR, Appleby JA, Hardy SC, et al. A prospective randomized clinical trial of liver preservation using high-sodium versus high-potassium lactobionate/raffinose solution. Transpl Int 1994; 7:S489.
138. Erhard J, Lange R, Scherer R, et al. Comparisonofhistidine-tryptophan- ketoglutarate (HTK) solution versus University of Wisconsin (UW) solution for organ preservation in human liver transplantation. A prospective, randomized study. Transpl Int 1994; 7: 177.
139. Chui AK, Thompson JF, Lam D, et al. Cadaveric liver procurement using aortic perfusion only. Aust N Z J Surg 1998; 68: 275.
140. Nardo B, Catena F, Cavallari G, et al. Randomized clinical study comparing UW and Celsior solution in liver preservation for transplantation: preliminary results. Transplant Proc 2001; 33: 870.
141. Cavallari A, Cillo U, Nardo B, et al. A multicenter pilot prospective study comparing Celsior and University of Wisconsin preserving solutions for use in liver transplantation. Liver Transpl 2003; 9: 814.
142. Garcia-Gil FA, Arenas J, Guemes A, et al. Preservation of the liver graft with Celsior solution. Transplant Proc 2006; 38: 2385.
143. Baskin-Bey ES, Washburn K, Feng S, et al. Clinical trial of the pan-caspase inhibitor, IDN-6556, in human liver preservation injury. Am J Transplant 2007; 7: 218.
144. Dondero F, Paugam-Burtz C, Danjou F, et al. A randomized study comparing IGL-1 to the University of Wisconsin preservation solution in liver transplantation. Ann Transplant 2010; 15: 7.
145. Hefty T, Fraser S, Nelson K, et al. Efficacy of UW vs Euro-Collins solution in paired cadaveric kidneys: a prospective study. Transplant Proc 1991; 23: 2370.
146. Baatard R, Pradier F, Dantal J, et al. Prospective randomized comparison of University of Wisconsin and UW-modified, lacking hydroxyethyl-starch, cold-storage solutions in kidney transplantation. Transplantation 1993; 55: 31.
147. Cho SI, Bradley JW, Garovoy MR, et al. Prospective controlled trial of cryoprecipitated plasma, plasma protein fraction and serum albumin solution for kidney preservation. Am J Surg 1981; 141: 441.
148. Polyak MM, Arrington BO, Kapur S, et al. Glutathione supplementation during cold ischemia does not confer early functional advantage in renal transplantation. Transplantation 2000; 70: 202.
149. van der Vliet JA, Kievit JK, Hene RJ, et al. Preservation of nonYheart-beating donor kidneys: a clinical prospective randomised case-control study of machine perfusion versus cold storage. Transplant Proc 2001; 33: 847. (Pubitemid 32237650)
150. Guarrera JV, Polyak MM, Arrington B, et al. Pushing the envelope in renal preservation; improved results with novel perfusate modifications for pulsatile machine perfusion of cadaver kidneys. Transplant Proc 2004; 36: 1257.
151. Kwiatkowski A, Wszola M, Kosieradzki M, et al. The early and long term function and survival of kidney allografts stored before transplantation by hypothermic pulsatile perfusion. A prospective randomized study. Ann Transplant 2009; 14: 14.